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Background: The dyslipidemia associated with obesity plays a major role in the development of atherosclerosis and
cardiovascular disease. Dyslipidemia in childhood can progress in adult stage. APOE is one of the most important genes
that regulate plasma lipid transport and clearance. The study aimed to assess whether the common APOE polymorphism
is associated with lipid profiles and dyslipidemia, and it could be modulated by obesity-related traits (body mass index,
waist circumference, hip circumference, and waist-to-hip ratio) in Vietnamese children.
Methods: A case-control study was designed including 249 cases with dyslipidemia and 600 controls without
dyslipidemia. Dyslipidemia is defined as elevated total or low-density lipoprotein (LDL) cholesterol levels, or low levels
of high-density lipoprotein (HDL) cholesterol. Genotype for APOE polymorphism (rs7412 and rs429358) was determined
by the polymerase chain reaction and restriction fragment length polymorphism method. The association of APOE
genotypes with plasma lipid disorders was tested by binary logistic regression analysis, taking into account the
confounding factors of age, sex, residence, province and obesity-related traits.
Results: In comparison with ε3/ε3 carriers, the ε4 carriers had the highest concentration of serum TC and LDL-C in
cases and controls (P≤ 0.001), while ε2 carriers had the lowest. Carriers without TT haplotype had higher serum TC
than those with TT haplotype. The ε4 carriers had higher hypoalphalipoproteinemia risk than ε3/ε3 carriers (OR = 2.78,
P = 0.02) before and after adjustment for age, gender, residence and obesity-related traits.
Conclusions: The study suggested that the APOE genotype and haplotype significantly associated with plasma TC and
LDL-C level in Vietnamese children. The association of APOE genotype with hypoalphalipoproteinemia was
independent of obesity-related traits.
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Dyslipidemia, abnormal of lipid levels in the blood, is a
leading risk factor for coronary artery disease (CAD),
hypertension, and stroke-the main cause of mortality
globally [1, 2]. Dyslipidemia includes hypercholesterol-
emia - high total cholesterol (TC) level, hyperbetalipo-
proteinemia - high low density lipoprotein-cholesterol
(LDL-C) level, hypoalphalipoproteinemia-reduced high* Correspondence: tqb@nihe.org.vn; binhnihe@yahoo.com
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hypertriglyceridemia-elevated triglyceride (TG) level. It
is especially alarming that the proportion of children
with dyslipidemia is increasing dramatically, propor-
tional to the percentage of overweight-obesity children
in both developed and developing countries. Dyslipid-
emia was observed in 85.3 % of the overweight children
and adolescents [3]. Percentages of 4–9 years old
Vietnamese overweight-obesity children had hypertrigly-
cemia, hypercholesterolemia, hyperbetalipoproteinemia
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progress in adult stage [5]. Therefore, the early detection
of lipoprotein disorders at a young age is very important
to prevent complications and decrease coronary heart
disease risk in future.
Dyslipidemia is well-known as a complex disorder
which is influenced by genetics and environmental fac-
tors [6–8]. There are many environmental factors related
to the plasma lipid profile, such as socioeconomic status,
diet and physical activity, and especially obesity. Obesity
leads to lipid abnormalities partly mediated by adipo-
kines and free fatty acids [9]. In obese individual, reduc-
tions in mRNA expression levels of lipoprotein lipase in
adipose tissue and lipoprotein lipase activity in skeletal
muscle along with competition for lipolysis between very
low density lipoprotein and chylomicrons result in de-
creased lipolysis of TG-rich lipoproteins [10, 11]. Com-
pared with normal-weight individuals, obese patients
present with elevated cholesterol synthesis [12]. There-
fore, obesity is probably the main cause of dyslipidemia.
The distribution of central fat determined by waist cir-
cumference was associated with abnormal of TG, LDL-
C, and HDL-C levels in children aged 5–17 years [13].
Besides, genetic factors are considered to be important
determinants of plasma concentrations of TC, TG, LDL-
C and HDL-C in adults [14]. APOE is one of the most
important genes that regulate plasma lipid transport and
clearance. APOE gene encodes for apolipoprotein E (apo
E) protein [15]. Apo E is also one of the central and well
established regulators of plasma lipid levels by affecting
the hepatic binding, uptake, and catabolism of several
classes of lipoproteins [16]. The 3 major isoforms of hu-
man apo E (E2, E3, and E4) coded by 3 alleles (ε2, ε3,
and ε4) differ in amino acid sequence at 2 sites, residue
112 (rs429358) and residue 158 (rs7412) [17]. These dif-
ferences alter APOE structure and function. The ε3 (112
cysteine-Cys, 158 arginine-Arg) allele is considered the
“neutral” APOE genotype while the ε4 (112 Arg and 158
Arg) and ε2 (112 Cys, 158 Cys) allele associated with
dyslipidemia in different adult populations [15, 18–20].
However, whether there is a difference between adults
and children in the role of APOE for determining plasma
lipid and lipoproteins is not clearly understood. Several
studies have reported the significant association of APOE
polymorphisms with lipid profile in Caucasian children
[21–24], while studies in Asian children showed incon-
sistent associations [25–27]. Furthermore, the effect of
the APOE polymorphism on the lipid profiles has been
reported to be modulated by obesity in children [28, 29].
Therefore, we focused on two key questions: (i) Are
APOE rs429358 and rs7412 polymorphisms significantly
associated with lipid profiles and dyslipidemia in
Vietnamese children? and (ii) whether the association
could be modulated by obesity-related traits?Methods
Study subjects
To identify the association between the common APOE
polymorphism and plasma lipid disorders in Vietnamese
children, we designed a case-control study in which 249
cases were children with hyperlipoproteinemia and 600
controls were children without hyperlipoproteinemia.
The study included 849 unrelated children aged 6–10
years: 567 children (405 boys and 162 girls) in Hanoi
City; 162 children (104 boys and 58 girls) in Thai
Nguyen province and 120 children (81 boys and 39 girls)
in Hai Duong province. All of them were Kinh-the major
ethnic group in Vietnam. The subjects had no evidence
of diseases related to atherosclerosis, coronary artery
diseases, diabetes and mental disorder. None of them
were using lipid-lowering medication when the blood
sample was taken.
Data collection
A questionnaire was provided along with consent forms
and parents were asked to provide information regarding
the child’s general health. The body weight of participants
was measured to the nearest 0.1 kg with standardized
medical scales. Subjects were weighed without shoes and
minimum of clothing. The height was measured to the
nearest 0.1 cm. Body mass index (BMI) was calculated as
weight divided by height squared (kg/m2). Waist circum-
ference (WC) was measured at the end of a normal expir-
ation to the nearest 0.1 cm at the mid-point between the
last floating rib and the top of the iliac crest. Hip circum-
ference (HC) was measured at the level of the symphysis-
pubis and the greatest gluteal protuberance. Waist-to-hip
ratio (WHR) was calculated as WC in cm divided by HC
in cm. Blood pressure was measured by using a standard-
ized automated sphygmomanometer (Omron HEM-6131,
Tokyo, Japan) after 5 min of rest in the seated position.
Blood pressure was measured in duplicate, with an inter-
val of at least 1 min. The mean of the 2 measurements
was used as the blood pressure value.
Lipid analysis
Blood lipids and lipoproteins were measured on samples
obtained after an overnight fast. Blood samples were col-
lected in EDTA containing tubes. Serum total cholesterol
(TC) and triglyceride (TG) were determined with enzym-
atic method. Serum high-density lipoprotein-cholesterol
(HDL-C) and low-density lipoprotein-cholesterol (LDL-C)
were measured through a direct assay. All determinations
were performed with autoanalyzer (Type Architect C8000;
Abbott Ltd., United States of America).
Dyslipidemia was diagnosed according to the criteria
of National Cholesterol Education Program [30] for TC
and LDL-C and US National Institutes of Health Heart,
Lung, and Blood Institute [31] for HDL-C and TG.
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(with children age under 10 years) or TG ≥ 130 mg/dL
(with children age uper 10 years). Hypercholesterolemia
was defined as TC ≥ 200 mg/dL. Hyperbetalipoproteine-
mia was defined as LDL-C ≥ 130 mg/dL. Hypoalphalipo-
proteinemia was defined as HDL-C ≤ 35 mg/dL. The
individuals with at least one of the four criteria above
were defined as dyslipidemia.
Genotyping method
Peripheral blood samples were obtained from each partici-
pants and genomic DNA was extracted from peripheral
blood leukocytes, using Wizard® Genomic DNA Purifica-
tion Kit (Promega Corporation, USA). Genotyping of the
APOE was performed by polymerase chain reaction and re-
striction fragment length polymorphism (PCR-RFLP)
method according to Hixson and Vernier [32] method with
some modification. The Fastdigest HhaI restriction enzyme
(Thermo Corporation, USA) was added directly to the reac-
tion system consisting of 244 base-pair PCR products
(3 μL) in a total 8.0 μL digested for 15 min at 37 °C. Each
reaction mixture was loaded onto 12 % polyacrylamide gel
and electrophoresised for 90 min at 150 V, 20 mA and
10 W. The digested product was visualized by UV illumin-
ation after Redsafe staining for 30 min. Each genotype pos-
sessed unique combination of HhaI fragment size. To
confirm the accuracy of the RFLP method, six random sam-
ples with different genotypes detected by the RFLP method
were also confirmed by direct sequencing. The PCR prod-
ucts were purified by low melting point gel electrophoresis
and phenol extraction, and then the DNA sequences were
analyzed by using the BigDye® Terminator v3.1 cycle se-
quencing kit chemistry in Axil Scientific Pte Ltd., Singapore.
The genotypes by RFLP method were in completed
concordance with those of the sequencing method.
Statistical analysis
Qualitative variables were expressed as percentages. Quan-
titative variables were expressed as means ± SD if variables
were normal distribution or median (interquartile range) if
variables were not normal distribution. Chi-square test or
one-way ANOVA or independent-sample t test or Kruskal-
Wallis test or Mann-Whitney U test were used when
appropriate. Allele frequency was determined for Hardy-
Weinberg equilibrium by Fisher’s exact test. The associ-
ation of genotypes with plasma lipid disorders was tested
by binary logistic regression analysis, taking into account
the confounding factors of age, sex, residence, province
and each of obesity-related traits including body mass
index (BMI), waist circumference (WC), hip circumference
(HC), and waist-to-hip ratio (WHR). The statistical ana-
lyses were done with the statistical software package
SPSS16.0 (SPSS Inc., Chicago, Illinois). To adjust the
threshold below which a P-value is considered significantfor multiple testing, we used a Bonferroni correction separ-
ately for each group of similar tests, taken into account the
linkage disequilibrium between two SNPs and correlation
among phenotypes. Specifically, P-values < 0.0125 were
considered as significant when comparing serum lipid pa-
rameters among APOE genotypes and haplotypes; P-values
< 0.025 were considered as significant when evaluating risk
factors for plasma lipid disorders.Results
Lipid profile and anthropometric characteristics of the
subjects in case and control groups are presented in
Table 1. There were significant differences between dyslip-
idemia and control groups in weight, BMI, WC, WHR,
TG, TC, LDL-C, and HDL-C. The genotypic distributions
for rs429358 and rs7412 were in Hardy-Weinberg equilib-
rium in controls (P > 0.05). There was the strong linkage
disequilibrium between two SNPs (D’ = 0.99, P = 0.0001).
TC haplotype had the highest frequency in all groups
(cases: 83.8 %; controls: 80.5 %). Frequencies of TT and
CC haplotypes were, respectively, 9.8 and 9.6 % in cases,
and 9.0 and 7.2 % in controls.
Lipid profile in cases and controls according to APOE
genotype is shown in Table 2. The ε4 carriers had the
highest concentration of serum TC and LDL-C in cases
and controls (P ≤ 0.001), while the ε2 carriers had the
lowest. The statistically significant differences among the
six genotype groups (ε2/ε2, ε2/ε3, ε3/ε3, ε2/ε4, ε3/ε4,
and ε4/ε4) were found in TC and LDL-C for both con-
trols and cases (P ≤ 0.001). Lipid profile in cases and
controls according to APOE haplotype is presented in
Additional file 1. In both cases and controls, there was a
significant difference of TC and LDL-C levels according
copy number of TT haplotype: Carriers without TT
haplotype had higher serum TC than those with TT
haplotype; carriers without TT haplotype had the highest
LDL-C level in cases (P < 0.0001).
We considered the relationship of some obesity-
related traits on blood lipid metabolism disorders, and
the results showed that there was a strong association
of BMI, WC, HC, WHR with TG, TC, HDL-C, and
LDL-C (P < 0.0001) (data not shown). Therefore, the
association between APOE polymorphism and dyslip-
idemia was further adjusted for obesity-related traits
(BMI, WC, HC, and WHR). Table 3 shows that APOE
genotype was significantly associated with hypoalphali-
poproteinemia before and after adjusting for BMI and
other covariates (age, gender, residence, and province).
The ε4 carriers had higher hypoalphalipoproteinemia
risk than theε3/ε3 carriers (OR = 2.78, P = 0.02). These
above similar associations were found after adjusting
for other obesity-related traits including WC, HC, and
WHR (Additional file 2).
Table 1 Characteristics of the study subjects
Parameter Controls (N = 600) Cases (N = 249) P-value
Male (%) 70.9 67.3 0.304
Age (years)b 7.9 (6.9–9.0) 7.9 (6.9–8.7) 0.811
Weight (kg)b 28.4 (22.1–36.0) 30.9 (23.6–38.1) 0.010
Height (cm)a 128.8 ± 9.2 126.6 ± 9.1 0.744
BMI (kg/m2)b 16.8 (15.0–21.8) 19.6 (15.6–22.9) <0.0001
Waist circumference (cm)b 56.0 (51.5–67.5) 67.2 (55.7–73.9) <0.0001
WHRa 0.87 ± 0.065 0.89 ± 0.068 <0.0001
Systolic blood pressure (mmHg)b 107.0 (100.0–115.0) 109.0 (100.0–117.0) 0.210
Diastolic blood pressure (mmHg)b 68.0 (60.0–74.0) 69.0 (60.0–75.5) 0.608
Triglyceride (mg/dL)b 62.0 (48.7–77.9) 120.4 (103.5–149.6) <0.0001
Total cholesterol (mg/dL)b 147.1 (131.6–163.5) 160.8 (141.5–188.3) <0.0001
HDL-C (mg/dL)b 54.4 (47.1–62.2) 47.1 (38.9–56.8) <0.0001
LDL-C (mg/dL)b 82.6 (72.3–96.3) 94.4 (78.1–119.1) <0.0001
BMI body mass index, WHR waist to hip ratio, HDL-C high-density lipoprotein-cholesterol, LDL-C low-density lipoprotein-cholesterol, TC total cholesterol
P-values obtained by Student T test or Mann–Whitney U test or Chi-square test. Bold values indicate significant difference between cases and controls
aData are mean ± SD
bData are median (interquartile range)
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We have examined the possible association of the APOE
rs429358 and rs7412 polymorphism with lipid profiles
and disorders in 600 normal and 249 dyslipidemia chil-
dren. The result showed that the APOE genotype was an
independent risk factor for hypoalphalipoproteinemia.
Obesity is the main cause of dyslipidemia because
obesity leads to impaired peripheral trapping and in-
creased fluxes of free fatty acids from adipocytes to the
liver and other tissues as well as hepatic overproduction
of very low density lipoprotein, decreased circulating TG
lipolysis and the formation of small dense LDL [9]. The
effect of the APOE polymorphism on the TC/HDL-C
and apo A-I/apo B ratios is modulated by BMI z-score
and adiponectin levels [29]. Therefore, it is crucial to in-
vestigate the association of APOE with dislylidemia,Table 2 Lipid profiles in cases and controls according to APOE geno
ε2 carriers ε3/ε3 carrie
Controls (N = 600)
TG 62.0 (49.3–79.7) 62.0 (48.7–7
TC 137.1 (123.0–151.9) 148.3 (134.6
HDL-C 54.4 (47.3–64.1) 54.8 (47.2–6
LDL-C 74.1 (69.9–89.3) 83.9 (72.8–9
Cases (N = 249)
TG 131.0 (106.2–156.6) 117.3 (102.7
TC 146.5 (126.9–167.9) 161.5 (141.4
HDL-C 47.1 (38.9–60.7) 47.8 (39.6–5
LDL-C 77.3 (70.1–99.4) 96.9 (81.2–1
TG triglyceride, TC total cholesterol, HDL-C high-density lipoprotein-cholesterol, LDL
Data are median (interquatile range). P-values obtained by Kruskall-Wallis test
Bold values indicate a statistically significant difference among APOE genotypes afteconsidering the contribution of obese status. In present
study, the significant association of APOE genotype with
hypoalphalipoproteinemia has been found before and
after adjustment of obesity-related traits in Vietnamese
primary school children. The ε4 carriers had higher
hypoalphalipoproteinemia risk than the ε3/ε3 carriers.
Regarding the relationship of APOE polymorphism with
plasma lipid levels, we have evaluated the influence of
genotype and haplotype. In both cases and controls, carriers
without TT haplotype had higher serum TC than those
with TT haplotype. Carriers without TT haplotype also had
the highest serum LDL-C in cases. The APOE genotype
analysis in our study indicated that the ε4 carriers had the
highest serum TC and LDL-C concentrations. There are
several studies supporting the association of this APOE
genoype with these plasma lipid concentrations in children.types in Vietnamese children (mg/dL)
rs ε4 carriers P-value
5.2) 64.6 (51.3–79.7) 0.319
–165.4) 149.6 (135.8–169.2) <0.0001
2.2) 52.1 (45.9–59.1) 0.236
6.6) 91.3 (76.6–104.4) <0.0001
–142.9) 122.1 (84.7–150.5) 0.520
–186.5) 177.7 (153.6–195.9) 0.001
6.4) 44.7 (35.8–54.7) 0.268
17.8) 112.1 (86.0–133.6) <0.0001
-C low-density lipoprotein-cholesterol
r adjustment for multiple testing (P-values < 0.0125)
Table 3 Univariate and multivariate analysis of association of APOE genotype with dyslipidemia and its componentsP-values
obtained by univariate logistic regression
OR (95 % CI) P-value OR* (95 % CI) P*-value
Hypoalphalipoproteinemia
APOE genotype ε3/ε3 1 1
ε2 carrier 1.19 (0.43–3.26) 0.739 1.29 (0.45–3.63) 0.635
ε4 carrier 2.68 (1.17–6.14) 0.020 2.78 (1.18–6.58) 0.020
Hyperbetalipoproteinemia
APOE genotype ε3/ε3 1 1
ε2 carrier 0.86 (0.29–2.56) 0.785 1.06 (0.33–3.35) 0.923
ε4 carrier 2.69 (1.22–5.94) 0.014 2.08 (0.85–5.10) 0.110
Hypertriglyceridemia
APOE genotype ε3/ε3 1 1
ε2 carrier 1.12 (0.72–1.74) 0.617 1.16 (0.72–1.86) 0.538
ε4 carrier 1.15 (0.71–1.86) 0.575 1.04 (0.62–1.75) 0.869
Hypercholesterolemia
APOE genotype ε3/ε3 1 1
ε2 carrier 0.64 (0.22–1.88) 0.421 0.76 (0.26–2.26) 0.624
ε4 carrier 1.82 (0.83–4.00) 0.138 1.62 (0.70–3.77) 0.259
rs429358 Dominant T/T 1 1
Dyslipidemia
APOE genotype ε3/ε3 1 1
ε2 carrier 1.06(0.70–1.60) 0.784 1.14 (0.73–1.77) 0.564
ε4 carrier 1.36 (0.89–2.08) 0.153 1.26 (0.80–1.99) 0.312
P*-values obtained by multivariate logistic regression and adjusted for age, gender, BMI, residence and province
Bold values indicate a statistically significant after adjustment for multiple testing (P-values < 0.025)
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centrations, and lower HDL-C concentration, compared
with ε3 carriers [23, 24, 29]. The present study observed no
statistically significant association between ε4 genotype and
HDL-C concentrations, in line with some studies [33, 34].
On the other hand, there were some investigations report-
ing that HDL-C concentration was statistically lower in ε4
carriers and higher in ε2 carriers [35, 36]. In this study, we
also reported that the ε2 carriers had the lowest serum TC
and LDL-C. The ε2 allele was associated with lower TC
and LDL-C and with higher HDL-C in the 21-year follow-
up study from childhood to adulthood in Young Finns
Study [23]. There has been a variation in the association be-
tween ε2 genotype and TG level among populations. Sev-
eral studies showed the significant association between ε2
genotype and TG level in Caucasian subjects [37, 38]. On
the other hand, in line with our report, several studies indi-
cated that there was no association between ε2 genotype
and TG concentration in both Caucasian and Asian sub-
jects [24, 26]. Thus, the association of ε2 genotype with TG
concentration varies by ethnicity. Taken together, the vari-
ant determination of APOE genotype on plasma lipid pro-
file may be due to demographic history, the age of the
study subjects or diet.The isoforms of apoE display different role in lipid me-
tabolism and preferences for specific classes of lipopro-
teins [39]. The apoE isoforms differ in their ability to
interact with some receptors (LDL receptor, the LDL
receptor-related protein, the VLDL receptor, the apoE
receptor-2, and gp330). The E4 isoform has a higher affin-
ity than E2 and E3 isoforms [40]. The different isoforms
vary in cholesterol absorption and postprandial remnant
clearance. As a result, this leads to down-regulation of
hepatic LDL-receptors in subjects with E4-isoform and an
increase in serum cholesterol levels [41, 42]. In addition,
ApoE isoform-specific activities may be explained by the
intramolecular domain interaction of the N-terminal (re-
ceptor binding region) and C-terminal (lipid-binding re-
gion) domains to determine the preference of apoE4 for
VLDL and of apoE3 and apoE2 for HDL [39].
To the best of our knowledge, our study is the initial
report on the potential association of APOE genotype
and haplotype with plasma lipid disorders in Vietnamese
children, independent of obesity-related traits. By com-
parison with adults, children are less influenced by
confounding environmental factors such as alcohol con-
sumption, use of medication, and the presence of un-
detected diseases. They may therefore be better subjects
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typic variability. The strength of the study is that the
sample size was fairly large and it could have the powers
between 0.85 and 0.92 to detect the association reported.
Meanwhile, there is a limitation of this study. We have
not yet considered the influence of diet and physical ac-
tivity to the association of the APOE polymorphism with
dyslipidemia in Vietnamese children.
Conclusions
In conclusion, our data reported that the APOE geno-
type and haplotype were significantly associated with
plasma TC and LDL-C level in Vietnamese children;
the association of APOE genotype with hypoalphalipo-
proteinemia was independent of obesity-related traits.
Additional files
Additional file 1: Table S1. Lipid profiles in cases and controls according
to APOE haplotypes in Vietnamese children (mg/dL). TG, triglyceride; TC, total
cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density
lipoprotein-cholesterol. Data are median (interquatile range). P-values
obtained by Kruskall-Wallis test. Bold values indicate a statistically significant
difference among copy number of TC, TT, and CC haplotype after adjustment
for multiple testing (P-values < 0.0125). (DOCX 19 kb)
Additional file 2: Table S2. Multivariate analysis of association for
dyslipidemia, adjusted for age, gender, residence, province and obesity-related
traits. P-values obtained by multivariate logistic regression and adjusted for
age, gender, residence, province, and waist circumference (P*-values) or hip
circumference (P**-values) or waist-to-hip ratio (P***-values). Bold values
indicate a statistically significant after adjustment for multiple testing
(P-values < 0.025). (DOCX 19 kb)
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